|
|
???tair.name??? >
???browser.page.title.title???
|
Showing items 651151-651175 of 2303271 (92131 Page(s) Totally)
<< < 26042 26043 26044 26045 26046 26047 26048 26049 26050 26051 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2018-09-10T03:51:09Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen, A.-L.;Hsu, C.-H.;Lin, J.-K.;Hsu, M.-M.;Ho, Y.-F.;She, T.-S.;Ko, J.-Y.;Lin, J.-T.;Lin, B.-R.;Wu, M.-S.;Yu, H.-S.;Jee, S.-H.;Chen, G.-S.;Chen, T.-M.;Chen, C.-A.;Lai, M.-K.;Pu, Y.-S.;Pan, M.-H.;Wang, Y.-J.;Tsai, C.-C.;Hsieh, C.-Y.; SHIOU-HWA JEE |
| 臺大學術典藏 |
2021-10-25T02:57:41Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; |Hsu C.-H; |Lin J.-K; |Hsu M.-M; |Ho Y.-F; |She T.-S; |JENG-YUH KO; |Lin J.-T; |Lin B.-R; |Wu M.-S; |Yu H.-S; |Jee S.-H; |Chen G.-S; |Chen T.-M; |Chen C.-A; |Lai M.-K; |Pu Y.-S; |Pan M.-H; |Wang Y.-J; |Tsai C.-C; |Hsieh C.-Y. |
| 國家衛生研究院 |
2021-03-01 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
|
Tsai, HJ;Shiah, HS;Chang, JY;Su, WC;Chiang, NJ;Chen, LT |
| 國立成功大學 |
2021-03-1 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
|
Tsai;Hui-Jen;Shiah;Her-Shyong;Chang;Jang-Yang;Su;Wu-Chou;Chiang;Nai-Jung;Chen;Li-Tzong |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
|
Ansell P; Motwani M; Wong S; Yue H; Wang L; Reilly E; Afar D; Naumovski L; Ramanathan R.K.; Strickler J.H; LoRusso P; Salgia R; Kang Y.-K; Yen C.J; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; Chia-Chi Lin; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. |
| 國立成功大學 |
2020 |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler, J.H.;LoRusso, P.;Salgia, R.;Kang, Y.-K.;Yen, C.J.;Lin, C.-C.;Ansell, P.;Motwani, Motwani M.;Wong, S.;Yue, H.;Wang, L.;Reilly, E.;Afar, D.;Naumovski, L.;Ramanathan, Ramanathan R.K. |
| 國家衛生研究院 |
2020-11-27 |
Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors
|
Shiah, HS;Chiang, NJ;Lin, CC;Yen, CJ;Tsai, HJ;Wu, SY;Su, WC;Chang, KY;Wang, CC;Chang, JY;Chen, LT |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah H.-S.; Chiang N.-J.; Chia-Chi Lin; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. |
| 國立成功大學 |
2021 |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah, H.-S.;Chiang, N.-J.;Lin, C.-C.;Yen, C.-J.;Tsai, H.-J.;Wu, S.-Y.;Su, W.-C.;Chang, K.-Y.;Wang, C.-C.;Chang, J.-Y.;Chen, L.-T. |
| 國家衛生研究院 |
2016-02 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors
|
Tsai, HJ;Chiang, NJ;Shiah, HS;Chang, KY;Su, WC;Chang, JY;Chen, LT |
| 國立成功大學 |
2016-02-01 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors.
|
Tsai, Hui-Jen; Chiang, Nai-Jung; Shiah, Her-Shyong; Chang, Kwang-Yu; Su, Wu-Chou; Chang, Jang-Yang; Chen, Li-Tzong |
| 國立臺灣大學 |
2011 |
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
|
陳培哲; CHEN, PEI-JER |
| 臺大學術典藏 |
2021-07-03T03:34:34Z |
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
|
Yau T.; PEI-JER CHEN; Chan P.; Curtis C.M.; Murphy P.S.; Suttle A.B.; Gauvin J.; Hodge J.P.; Dar M.M.; Poon R.T. |
| 臺大學術典藏 |
2018 |
Phase I investigator's perceptions to 'supersized seamless trials in oncology'
|
Ma B.B.Y; van der Velden N; Mo F; Loong H.H; Siu L; Goh B.C; Bang Y.-J; Chia-Chi Lin; Desai J; Lolkema M.P. |
| 中山醫學大學 |
2021 |
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
|
Park, K; Chang, GC; Curigliano, G; Lim, WT; Soo, RA; Molina-Vila, MA; Cattan, V; Darville, H; Gandossi, E; Smutna, V; Sudey, I; Viteri, S |
| 國家衛生研究院 |
2013-12 |
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
|
Finn, RS;Poon, RTP;Yau, T;Klümpen, HJ;Chen, LT;Kang, YK;Kim, TY;Gomez-Martin, C;Rodriguez-Lope, C;Kunz, T;Paquet, T;Brandt, U;Sellami, D;Bruix, J |
| 國家衛生研究院 |
2021-03-30 |
Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia
|
Tsai, HJ;Hsiao, HH;Hsu, YT;Liu, YC;Kao, HW;Liu, TC;Cho, SF;Feng, X;Johnston, A;Bomalaski, JS;Kuo, MC;Chen, TY |
| 國立成功大學 |
2021-05 |
Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia
|
Tsai;Hui-Jen;Hsiao;Hui-Hua;Hsu;Ya-Ting;Liu;Yi-Chang;Kao;Hsiao-Wen;Liu;Ta-Chih;Cho;Shih-Feng;Feng;Xiaoxing;Johnston;Amanda;Bomalaski;John, S.;Kuo;Ming-Chung;Chen;Tsai-Yun |
| 國家衛生研究院 |
2020-05 |
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer
|
Yoo, C;Oh, DY;Choi, HJ;Kudo, M;Ueno, M;Kondo, S;Chen, LT;Osada, M;Helwig, C;Dussault, I;Ikeda, M |
| 國立成功大學 |
2020 |
Phase i study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
|
Yoo, C.;Oh, D.-Y.;Choi, H.J.;Kudo, M.;Ueno, M.;Kondo, S.;Chen, L.-T.;Osada, M.;Helwig, C.;Dussault, I.;Ikeda, M. |
| 國立臺灣大學 |
2006 |
PHASE I STUDY OF BIWEEKLY GEMCITABINE FOLLOWED BY OXALIPLATIN AND SIMPLIFIED 48-H INFUSION OF FLUOROURACIL/LEUCOVORIN FOR ADVANCED PANCREATIC CANCER
|
CHANG, HUI-JU; WANG, CHUAN-CHENG; CHENG, ANN-LII; HSU, CHIUN; LU, YEN-SHEN; CHANG, MING-CHU; LIN, JAW-TOWN; WANG, HSIU-PO; LIU, TSANG-WU; CHANG, JANG-YANG; WHANG-PENG, JACQUELINE; CHEN, LI-TZONG; 張慧如; 王全正; 鄭安理; 許駿; 盧彥伸; 章明珠; 林肇堂; 王秀伯; 劉滄梧; 張俊彥; 彭汪嘉康; 陳立宗 |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J.;Wang C.-C.;Cheng A.-L.;Chiun Hsu;Lu Y.-S.;Chang M.-C.;Lin J.-T.;Wang H.-P.;Shiah H.-S.;Liu T.-W.;Chang J.-Y.;Whang-Peng J.;Chen L.-T.; Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Chiun Hsu; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J;Wang C.-C;Cheng A.-L;Hsu C;Yen-Shen Lu;Chang M.-C;Lin J.-T;Wang H.-P;Shiah H.-S;Liu T.-W;Chang J.-Y;Whang-Peng J;Chen L.-T.; Ch'ang H.-J; Wang C.-C; Cheng A.-L; Hsu C; YEN-SHEN LU; Chang M.-C; Lin J.-T; Wang H.-P; Shiah H.-S; Liu T.-W; Chang J.-Y; Whang-Peng J; Chen L.-T. |
| 臺大學術典藏 |
2021-01-15T03:47:43Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Hsu C.; Lu Y.-S.; Chang M.-C.; Lin J.-T.; HSIU-PO WANG; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
Showing items 651151-651175 of 2303271 (92131 Page(s) Totally)
<< < 26042 26043 26044 26045 26046 26047 26048 26049 26050 26051 > >>
View [10|25|50] records per page
|
